STOCK TITAN

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

SLNO

Soleno Therapeutics (SLNO) last traded on May 15, 2026. A Form 15-12G filed on May 28, 2026 ends the SEC registration of its shares.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
29 252 sessions, May 15, 2025 to May 15, 2026
Largest daily move
+32.3% close of April 6, 2026
1-year change
-29.4% closing prices, May 15, 2025 to May 15, 2026
1-month change
+0.8% closing prices, April 15, 2026 to May 15, 2026

Company Description

Written before these shares stopped trading.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. According to the company’s public disclosures and news releases, Soleno’s work centers on addressing significant unmet medical needs in rare genetic conditions, with a particular emphasis on Prader-Willi syndrome (PWS) and its hallmark symptom, hyperphagia.

Soleno’s first commercial product is VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR. Company materials describe VYKAT XR as a once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is commercially available to patients in the United States. Soleno reports that VYKAT XR is the first FDA-approved treatment for hyperphagia in people living with PWS.

Business focus and therapeutic area

Soleno characterizes itself as a company developing therapeutics for rare diseases. Its current commercial and clinical activities highlighted in recent press releases are concentrated on PWS, a rare genetic neurodevelopmental disorder. The company’s disclosures explain that PWS is caused by an abnormality in gene expression on chromosome 15 and occurs in an estimated one in every 15,000 live births, based on data from the Prader-Willi Syndrome Association USA.

The company emphasizes hyperphagia as the defining symptom of PWS. Hyperphagia is described as a chronic and life‑threatening condition marked by an intense, persistent sensation of hunger, food preoccupations, an extreme drive to consume food, food‑related behavior problems, and a lack of normal satiety. Company materials note that hyperphagia can severely diminish quality of life for individuals with PWS and their families and can contribute to serious outcomes, including mortality and longer‑term comorbidities such as diabetes, obesity, and cardiovascular disease.

VYKAT XR and its clinical program

Soleno’s public communications state that VYKAT XR is a proprietary extended‑release formulation of diazoxide choline and that it is administered once daily. The company reports that VYKAT XR’s approval was supported by a comprehensive Phase 3 clinical program in PWS, including placebo‑controlled and long‑term open‑label studies and a 16‑week randomized withdrawal study (C602‑RWP). In this withdrawal study, participants who were switched from VYKAT XR (also referred to as diazoxide choline extended‑release tablets or DCCR) to placebo experienced a statistically significant worsening of hyperphagia scores compared with those who remained on treatment.

According to Soleno’s summary of the JCEM publication, the randomized withdrawal study included individuals 4 years and older with hyperphagia due to PWS who had previously completed earlier Phase 3 studies. The primary endpoint was change from baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ‑CT) total score, with secondary endpoints including Clinical Global Impression of Severity and Improvement. Exploratory endpoints included weight and body mass index (BMI) z‑score. The company reports that adverse events were similar between treatment arms, with no serious adverse events in the DCCR treatment arm and no discontinuations due to adverse events in that study.

Indication and safety information for VYKAT XR

Across multiple press releases, Soleno reiterates the indication for VYKAT XR: treatment of hyperphagia in adults and pediatric patients 4 years of age and older with PWS. The company also summarizes key elements of the product’s Important Safety Information as presented in its communications:

  • Contraindications: Use of VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
  • Hyperglycemia: Hyperglycemia, including diabetic ketoacidosis, has been reported. Company materials state that fasting plasma glucose (FPG) and HbA1c should be tested before initiating VYKAT XR, that blood glucose should be optimized in patients who have hyperglycemia, and that fasting glucose and HbA1c should be monitored during treatment, with more frequent monitoring early in therapy for patients with risk factors for hyperglycemia.
  • Risk of fluid overload: Edema, including severe reactions associated with fluid overload, has been reported. The company advises monitoring for signs or symptoms of edema or fluid overload and notes that VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
  • Common adverse reactions: The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) reported in company materials include hypertrichosis, edema, hyperglycemia, and rash.

Soleno’s communications direct readers to the full Prescribing Information, including Medication Guide, for complete safety and dosing details.

Commercialization and financial milestones

Soleno reports that VYKAT XR was launched commercially in the United States following FDA approval. In its public financial updates, the company has highlighted product revenue from U.S. sales of VYKAT XR and related operating metrics, such as patient start forms, unique prescribers, coverage levels, and active patients on therapy. The company has also disclosed that it achieved profitability and positive cash flow following the launch of VYKAT XR, based on its reported financial results.

In addition, Soleno’s Board of Directors authorized a $100 million accelerated share repurchase (ASR) program, as described in an 8‑K filing and related press release. Under the ASR Agreement with Jefferies LLC, Soleno prepaid the purchase price and received an initial delivery of shares, with the final number of shares to be determined based on the volume‑weighted average price of its common stock over the term of the transaction, subject to agreed terms and adjustments. The company also entered into a first amendment to its loan agreement with Oxford Finance LLC and lenders to, among other things, permit the ASR and modify the availability of certain term loans.

Regulatory and safety communications

Through an 8‑K filed under Regulation FD, Soleno disclosed that it became aware of a serious adverse event reported in the FDA’s Adverse Event Reporting System involving a patient who died from an apparent pulmonary embolus. The company reports that the treating physician assessed the case as not related to treatment with VYKAT XR and that Soleno’s assessment is the same. In that disclosure, the company reiterates that VYKAT XR was approved following a rigorous clinical program and that it is committed to reporting adverse events in accordance with applicable law. Soleno also references FDA statements that reports in FAERS do not establish causation and may reflect underlying disease or other factors.

Corporate governance and investor relations

Soleno’s SEC filings and press releases describe ongoing corporate governance developments, including the appointment of an additional independent director with extensive biopharmaceutical finance experience to its Board and Audit Committee. The company also notes the passing of a long‑serving Board member who chaired its Audit Committee and indicates that another Board and Audit Committee member is expected to assume the role of Audit Committee Chair.

The company regularly participates in healthcare and investor conferences and hosts earnings calls and webcasts to discuss financial results and operational updates. These activities are disclosed in 8‑K filings and press releases and are part of the company’s communication with existing and potential investors.

Stock listing and regulatory status

According to recent 8‑K filings, Soleno Therapeutics’ common stock trades on the NASDAQ under the symbol SLNO. The filings list the company’s common stock, $0.001 par value, as registered under Section 12(b) of the Securities Exchange Act of 1934. The filings also reference the company’s loan agreements, equity incentive plans, and other corporate documents as exhibits.

Industry classification

For industry classification purposes, Soleno is described in the provided data as operating within Surgical and Medical Instrument Manufacturing in the Manufacturing sector, while its own disclosures consistently describe it as a biopharmaceutical company focused on rare diseases. Its primary publicly discussed activities involve pharmaceutical development, clinical research, regulatory interactions, and commercialization of a prescription medicine for a rare genetic disorder.

Stock Performance

$53.01
No recent trading
Last close: May 15, 2026
-29.4%
1 year to May 15, 2026
52.1M
Shares outstanding As of April 29, 2026.

Soleno Therapeutics (SLNO) closed at $53.01 on May 15, 2026. In the 12 months to May 15, 2026, the price lost 29.4%.

See what a $1,000 investment in SLNO was worth at its last close

SLNO Metrics & Rankings

Price returns through May 15, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Soleno Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include acquisition, management, earnings, earnings date. View all SLNO news →

Financial Highlights

Soleno Therapeutics generated $190.4M in revenue in FY2025, retaining a 98.6% gross margin, operating income reached $9.4M (4.9% operating margin), and net income was $20.9M, reflecting a 11.0% net profit margin. Diluted earnings per share stood at $0.39. The company generated $46.8M in operating cash flow. The current ratio was 5.80, measuring current assets divided by current liabilities.

$190.4M
Revenue (FY2025)
$20.9M
Net Income (FY2025)
$46.8M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for SLNO.

Short Interest History

Last 12 Months

Short interest in Soleno Therapeutics (SLNO) currently stands at 4.4 million shares, down 32.5% from the previous reporting period, representing 8.6% of the float. Since November 2025, short interest has decreased by 51.6%.

Days to Cover History

Last 12 Months

Days to cover for Soleno Therapeutics (SLNO) currently stands at 2.3 days, down 19.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 58%. Across the settlements charted above, it has ranged from 1.0 to 9.6 days.

SLNO Company Profile & Sector Positioning

Soleno Therapeutics (SLNO) operates in the Biotechnology industry within the broader Healthcare sector.

Investors comparing SLNO often look at related companies in the same sector, including Minerva Neurosciences, Inc (NERV), uniQure N.V. (QURE), Zevra Therapeutics, Inc. (ZVRA), Altimmune, Inc. (ALT), and BridgeBio Pharma, Inc. (BBIO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SLNO's relative position within its industry.

Frequently Asked Questions

Soleno Therapeutics (SLNO) last traded on May 15, 2026. A Form 15-12G filed on May 28, 2026 ends the SEC registration of its shares.

Soleno Therapeutics (SLNO) has no recent trading. Its last close was $53.01 on May 15, 2026.

The FY2025 revenue of Soleno Therapeutics (SLNO) is $190.4M, from its most recent completed fiscal year.

The FY2025 net income of Soleno Therapeutics (SLNO) is $20.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Soleno Therapeutics (SLNO) is $0.39 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Soleno Therapeutics (SLNO) is $46.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Soleno Therapeutics (SLNO) is 11.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Soleno Therapeutics (SLNO) is 4.9% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Soleno Therapeutics (SLNO) is 98.6% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Soleno Therapeutics (SLNO), current assets divided by current liabilities, was 5.80 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Soleno Therapeutics (SLNO) is $187.7M for FY2025, its most recent completed fiscal year.

The operating income of Soleno Therapeutics (SLNO) is $9.4M for FY2025, its most recent completed fiscal year. Learn about operating income.